What are the Priorities for Pharmacovigilance in LMICS during the COVID-19 Pandemic?

It is well documented that Pharmacovigilance (PV) activities have not been seen as a healthcare priority in developing countries. Despite good progress being made, PV capacity across LMICs in general remains weak, evidenced by poor awareness, low reporting numbers and a lack of adequate PV systems.
Given the impact that the ongoing COVID-19 pandemic is having upon health systems globally, it is essential to ensure that PV systems in LMICs have the capacity to address both the novel, and exacerbated pre-existing challenges that they are now facing.
Following on the results of a The Global Health Network’s globalpharmacovigilance.org survey on pharmacovigilance priorities join us to further determine consensus on PV priorities.
The workshop will feature a presentation of the survey results, and a discussion of the top priorities identified with a focus on:
How and if these issues apply to where you work?
What other PV concerns you might have?